Giving sight to the developing world

Article

OTE's Victoria Farrell interviews Cambodian paediatric ophthalmologist Phara Khauv to find out how an ORBIS initiative has impacted his practice in a vastly underserved country.

Key Points

Preventable blindness still affects an unacceptably high proportion of the world's population. The World Health Organization estimates that 28 million of the world's 37 million blind suffer from preventable blindness: that's a staggering 75.7% of the world's total population of blind people. The vast majority of the needlessly blind - 90% in fact - live in the developing world.

In 1982, a non-profit organization, ORBIS International was established. The goal of the organization is to increase access to vision care services in these countries, with the goal of eventually eliminating preventable blindness.

The fellowship programme

In addition to the training programmes and the services provided by the Flying Eye Hospital, ORBIS also, in collaboration with its partner FedEx, offers fellowships to ophthalmologists from developing regions.














The programme was launched in 2006; three fellows have since been named and have undertaken courses, and a further two will be designated annually for the next five years.

Previous FedEx Fellows include Dr Thomas Cherian of the Little Flower Hospital in Kerala, India, who completed his fellowship in the areas of retina, paediatric retina and retinopathy of prematurity at Moorfields Eye Hospital, UK, and Dr Nguyen Thanh Chi of Vietnam's Da Nang Eye Hospital, who studied paediatric ophthalmology at Stanford University, US.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.